Market capitalization | $83.39m |
Enterprise Value | $76.82m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 153.64 |
P/S ratio (TTM) P/S ratio | 166.78 |
P/B ratio (TTM) P/B ratio | 11.75 |
Revenue (TTM) Revenue | $500.00k |
EBIT (operating result TTM) EBIT | $-4.95m |
As a Free StocksGuide user, you can view scores for all 6,807 stocks worldwide.
1 Analyst has issued a forecast Exicure Inc:
1 Analyst has issued a forecast Exicure Inc:
Dec '24 |
+/-
%
|
||
Revenue | 0.50 0.50 |
-
|
|
Gross Profit | -0.32 -0.32 |
77%
77%
|
|
EBITDA | -4.13 -4.13 |
67%
67%
|
EBIT (Operating Income) EBIT | -4.95 -4.95 |
65%
65%
|
Net Profit | -9.70 -9.70 |
43%
43%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Exicure, Inc. is a clinical-stage biotechnology company, which engages in the discovery, research, and development of treatments based on spherical nucleic acid technology (SNA). It focuses on neurology, immuno-oncology, inflammatory diseases, and other genetic disorders. The company was founded by Chad A. Mirkin and Colby Shad Thaxton in 2011 and is headquartered in Skokie, IL.
Head office | United States |
CEO | Andy Yoo |
Employees | 7 |
Founded | 2011 |
Website | www.exicuretx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.